non-opioid pain drugs – Talk Bio

Actionable Insights Powered by AI

Vertex Drops Next-Generation Pain Drug After Phase 2 Failure, Casts Doubt on Broader Journavx Expansion

1 month ago talkbio0Tagged Acute onset pain, Approved, Drug Development, Journavx, non-opioid pain drugs, Pain management, Peripheral neuropathic pain, Sodium Channel Blockers, United States Food and Drug Administration, VX-993

Vertex Pharmaceuticals; Journavx; VX-993; pain management; acute pain; phase 2 clinical trial; sodium channel inhibitor; non-opioid pain drugs; FDA approval; peripheral neuropathic pain; drug development

Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic

6 months ago talkbio0Tagged Acute onset pain, biotherapeutics, Chronic pain, Clinical Trials, inhibitors, Latigo, non-opioid pain drugs, SCN10A gene, Series B

Latigo Biotherapeutics, non-opioid pain drugs, Nav1.8 inhibitors, Series B funding, clinical trials, acute pain, chronic pain